Entinostat's epigenetic mechanism may reverse resistance to hormonal therapy, delaying the need for toxic chemotherapeutic agents and improving survival when given in combination with aromatase inhibitors
But I never addressed the joint and muscle pain that often accompanies the use of aromatase inhibitors
Bone mineral density decreased over time in the exemestane group; however, patients on the aromatase inhibitor
had no increased risk of fractures.
block the enzyme aromatase, which is responsible for conversion of the adrenal derived precursor, androstenedione, to estrogen in tissues such as fat, muscle, and in the breast in postmenopausal women.
Effect of an aromatase inhibitor
on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
This is the first head-to-head study of these two aromatase inhibitors
in the post-surgery setting and is expected to enrol 4,000 women worldwide.
Liz Caroll, from charity Breast Cancer Care, said: "These results further suggest the benefits of using aromatase inhibitors
over tamoxifen in treating early invasive breast cancer and indicate that many more lives could be saved.
Coordinated by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), the ExCel research study will examine the potential benefit of the aromatase inhibitor
In a recent trial comparing the aromatase inhibitor
anastrozole (Arimidex) with tamoxifen, anastrozole significantly decreased spinal and hip bone mass after a median follow-up of 33 months, compared with tamoxifen.
Exemestane is a type of drug called an aromatase inhibitor
which stops natural production of oestrogen, the hormone responsible for the growth and recurrence of many breast cancers.
Methods: Ten male patients with a diagnosis of IHH/PE were treated with the aromatase inhibitor
anastrazole (1 mg/d orally).
Under the agreement, the Geneva-based company will have the rights to develop, register and market the aromatase inhibitor
The study showed that entinostat extended both progression-free survival and overall survival when added to exemestane in postmenopausal women with estrogen receptor-positive (ER+) breast cancer whose cancer had progressed after treatment with a nonsteroidal aromatase inhibitor
Indeed, ongoing clinical trials are comparing outcomes with 10 versus the standard 5 years of adjuvant aromatase inhibitor
The approved indications are for increasing bone mass in women at high risk for fracture on adjuvant aromatase inhibitor
therapy for breast cancer and in men at high risk for fracture on androgen deprivation therapy (ADT) for non-metastatic prostate cancer, the company's statement said.